Actualités de Paris

Sanofi Diabetes

Sanofi Announces the CE Mark for JuniorSTAR®, a New Half-Unit Insulin Reusable Pen for People with Type 1 Diabetes

Paris (ots/PRNewswire) - Sanofi announced today at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, the CE Mark of JuniorSTAR(R), a new halfunit insulin reusable pen that can be used with Lantus(R) (insulin glargine), Apidra(R) (insulin glulisine) or Insuman(R) ...

Sanofi

Sanofi announces upcoming launch of MyStar Extra®, the first self- monitoring blood glucose meter with estimated A1c

Paris (ots) - - CE marks obtained for MyStar Extra® and MyStar SylkFeel® lancing device, respectively, enabling commercialization in the European Union - Scientific data presented at EASD 2013 demonstrate robustness and accuracy[i],[ii] of estimated A1c algorithm in MyStar Extra® At the annual meeting of the ...

Sanofi Diabetes

Data Show Sanofi's Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled

Paris (ots/PRNewswire) - - Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin - Sanofi announced today new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia(R) (lixisenatide), when added to basal insulin, were greatest in patients with ...

Renault-Nissan Alliance

Renault-Nissan Sells its 100,000th Zero-Emission Car

Paris (ots/PRNewswire) - - American graduate student took delivery of the 100,000th electric vehicle - Renault-Nissan EVs outsell all other major automakers combined - Nissan LEAF remains world's best-selling EV - With its latest EV ZOE, Renault expands its zero-emission lineup and reinforces its leadership in Europe The Renault-Nissan Alliance has sold its 100,000th zero-emission car. To view the Multimedia News Release, ...

Nestlé Nespresso SA

Nespresso Builds on 10 Years of Success of its AAA Sustainable Quality Program in Cooperation with the Rainforest Alliance, Announcing:

Sanofi Diabetes

Lyxumia® is First Diabetes Therapy of its Class Approved in Japan for use in Combination with Basal Insulin

Paris (ots/PRNewswire) - - First once-daily prandial GLP-1 receptor agonist offering a new treatment option for Japanese people living with type 2 diabetes - Sanofi announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the manufacturing and distribution of Lyxumia(R) (lixisenatide) ...

Renault-Nissan Alliance

Renault-Nissan Alliance Posts Record Synergies of 2.69 Billion Euros in 2012, with Particular Gains in Emerging Markets

Paris (ots/PRNewswire) - - Synergies up 54% from 1.75 billion euros in previous year - Sharp increase shows partnership's momentum keeps accelerating - Purchasing, powertrain and vehicle engineering areas remain the biggest contributors - Synergies expected to keep growing with acceleration in non-engineering areas ...

Sanofi Diabetes

Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300

Paris (ots/PRNewswire) - - EDITION I demonstrated similar blood sugar control with fewer night-time low blood sugar events compared to Lantus(R)- - Topline results of EDITION II consistent with EDITION I findings - Sanofi announced today that the first phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with ...

Sanofi Diabetes

Sanofi to Present New Clinical Data, Including Results From the Investigational New Insulin U300, at the American Diabetes Association 73rd Scientific Sessions

Paris (ots/PRNewswire) - Sanofi announced today that clinical data highlighting the company's ongoing commitment to advancing diabetes care will be presented at the American Diabetes Association (ADA) 73rd Scientific Sessions in Chicago, USA (June 21-25, 2013). In total, more than 60 abstracts representing new data ...

Bristol-Myers Squibb GmbH & Co. KGaA

ORENCIA® (abatacept) Shows Comparable Efficacy to Humira® (adalimumab) in Year Two Data from Head-to-Head Study in Patients with Moderate to Severe Rheumatoid Arthritis

Paris (ots/PRNewswire) - AMPLE Study results highlighted during a press conference at the European League Against Rheumatism (EULAR) Annual congress - Year 2 data shows similar efficacy between ORENCIA plus methotrexate (MTX) and Humira plus MTX, consistent with the year 1 result which demonstrated comparable ...

Democratic Republic of the Congo

The Democratic Republic of the Congo Fixes October 2015 as the Date for the Launch of the First Phase of the Largest Hydroelectric Plant in the World

Paris (ots/PRNewswire) - Following the initialling of an energy cooperation treaty between the Democratic Republic of the Congo and the Republic of South Africa on 7 March 2013, the DRC has now re-launched the process for the selection of a developer and established the objective of laying the first foundation stone ...

Altuglas - Arkema Group

Altuglas®, a Partner of the Film "Mood Indigo" of Michel Gondry

Paris (ots/PRNewswire) - Altuglas International, a subsidiary of the Arkema Group is a partner of the film Mood Indigo coming to theather today. This is the film adaptation of the eponymous book of the french author Boris Vian published in 1947. To view the Multimedia News Release, please click: http://www.multivu.com/mnr/60651-altuglas-partner-film-mood-indigo-michel-gondry Michel Gondry, the famous Director has swarmed ...

WISeKey SA

WISeKey and Qwant launch a Joint Venture WISeQwant providing Next Generation ID based Social Mobile Search for Fan Ecosystems

Geneva, Switzerland/Paris, France (ots) - Following on the partnership announced last year WISeKey and Qwant have launched a Joint Venture with the name WISeQwant.com associating WISekey's digital identity management, mobile apps and encryption with Qwant Search technologies. WISeQwant defines a new paradigm for ...

Sanofi Diabetes

Sanofi Announces Call for Submissions for Ignite: The Diabetes Ideas Challenge

Paris (ots/PRNewswire) - - Worldwide invitation to create and submit concepts for a potential next-generation insulin delivery device - Sanofi announced today that it is accepting submissions for Ignite: The Diabetes Ideas Challenge ("Ignite Challenge"). The web-based Ignite Challenge invites patients, caregivers, designers, engineers, and innovators from around the ...

OneAccess and Eutelsat Communications

Eutelsat and OneAccess Launch Innovative Technology for Advanced Enterprise Services on KA-SAT Satellite

Paris (ots/PRNewswire) - New generation of performance-enhanced satellite-based VPN services immediately available across entire KA-SAT coverage in Europe, the Middle East and North Africa Eutelsat Communications and OneAccess, the leading manufacturer of multi-service routers and Carrier Ethernet access devices, ...

Etam Lingerie

Etam Opens Fashion Week

Paris (ots/PRNewswire) - On 26 February 2013, Etam will open Fashion Week with its "Girls Only!" Live Show at the Bourse de Commerce (Paris 1st arrondissement). "GIRLS ONLY!" For this sixth edition, the Etam Lingerie and Natalia Vodianova for Etam collections will once again create a buzz to the sounds of the new international women's musical scene, under the artistic direction of Mark Ronson. To view the Multimedia News Release, please click: ...

Sanofi

Sanofi Demonstrates Commitment to Innovative Diabetes Care at International Diabetes Technology Conference

Paris, France (ots) - - Data presented at ATTD by Sanofi will focus on the company's integrated portfolio of therapeutic solutions, blood glucose monitoring, insulin delivery and contributions to advancing diabetes research - Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that its comprehensive portfolio of ...

Renault-Nissan Alliance

Renault-Nissan Alliance Posts Sales Record in 2012 for 4th Straight Year

Paris (ots/PRNewswire) - - Despite recession in Europe and slowing pace of sales in China, global sales were a record 8.1 million units - Strongest growth came from emerging markets and the United States - Zero-emission sales up more than 80% from 2011 The Renault-Nissan Alliance sold a record 8,101,310 vehicles in 2012, representing one in 10 new cars sold worldwide. ...

Sanofi Diabetes

Once-Daily Lyxumia® (lixisenatide) Approved for Treatment of Type 2 Diabetes in Europe

Paris (ots/PRNewswire) - - Sanofi portfolio expands to offer first once-a-day prandial GLP-1 receptor agonist - Sanofi announced today that the European Commission has granted Marketing Authorisation in Europe for Lyxumia(R) (lixisenatide). Lyxumia(R), the first once-daily prandial GLP-1 receptor agonist, is ...

Bristol-Myers Squibb GmbH & Co. KGaA

Bristol-Myers Squibb Launches an Online Resource for Patients with Chronic Myeloid Leukaemia in 15 European Countries

Paris (ots/PRNewswire) - My CML Life Online Resource Centre Empowers and Guides Patients with CML Through Different Stages of Their Journey Bristol-Myers Squibb Company today announced the introduction of "My CML Life", a disease awareness website for patients with chronic myeloid leukaemia (CML). In recognition of ...

Bristol-Myers Squibb GmbH & Co. KGaA

Subcutaneous Formulation of ORENCIA® (abatacept) Approved by European Commission

Paris (ots/PRNewswire) - Proven biologic is first therapy available in both subcutaneous and intravenous formulations for adults with moderate to severe active rheumatoid arthritis Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA(R) (abatacept), in combination with ...

NTT Communications

NTT Communications Takes AFP into the Digital Era

Paris (ots/PRNewswire) - NTT Communications, a member of the NTT Group and the number one Fortune Global 500 telecommunications group, has been a loyal supplier since 1998 to Agence France-Presse (AFP), a global news agency delivering fast, worldwide news. Through its ability to deliver a quality and responsive service, NTT Communications has consistently been able to meet the demands of AFP's increased flow of ...

Boston Scientific

PRECISION? PLUS SPINAL CORD STIMULATOR System Receives CE Mark Approval as MRI Conditional

Paris (ots/PRNewswire) - Boston Scientific Corporation has received CE Mark approval for use of its PRECISION(TM) PLUS SPINAL CORD STIMULATOR (SCS) System in patients with the system and are in need for magnetic resonance imaging (MRI) head-only scans. The PRECISION PLUS SCS System is the world's first rechargeable SCS device. This approval provides physicians with an ...

Boston Scientific

PRECISION? PLUS SPINAL CORD STIMULATOR System Receives CE Mark Approval for Peripheral Nerve Stimulation

Paris (ots/PRNewswire) - Boston Scientific Corporation has received CE Mark approval for use of its PRECISION(TM) PLUS SPINAL CORD STIMULATOR (SCS) System, the world's first rechargeable SCS device, in peripheral nerve stimulation for patients with chronic intractable pain of the trunk. Peripheral nerve stimulation ...